Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 27;15(2):127-141.
doi: 10.4240/wjgs.v15.i2.127.

Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines

Affiliations
Review

Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines

Marco Biolato et al. World J Gastrointest Surg. .

Abstract

Cirrhotic patients with severe thrombocytopenia are at increased risk of bleeding during invasive procedures. The need for preprocedural prophylaxis aimed at reducing the risk of bleeding in cirrhotic patients with thrombocytopenia who undergo scheduled procedures is assessed via the platelet count; however, establishing a minimum threshold considered safe is challenging. A platelet count ≥ 50000/μL is a frequent target, but levels vary by provider, procedure, and specific patient. Over the years, this value has changed several times according to the different guidelines proposed in the literature. According to the latest guidelines, many procedures can be performed at any level of platelet count, which should not necessarily be checked before the procedure. In this review, we aim to investigate and describe how the guidelines have evolved in recent years in the evaluation of the minimum platelet count threshold required to perform different invasive procedures, according to their bleeding risk.

Keywords: Avatrombopag; Liver disease; Lusutrombopag; Thrombocytopenia; Transfusion.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Biolato M and Grieco A received personal fees from SOBI s.r.l. and Shionogi B.V. Other authors declare no conflict of interests relevant to this manuscript.

Similar articles

Cited by

References

    1. Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int . 2017;37:778–793. - PubMed
    1. Buckley MF, James JW, Brown DE, Whyte GS, Dean MG, Chesterman CN, Donald JA. A novel approach to the assessment of variations in the human platelet count. Thromb Haemost . 2000;83:480–484. - PubMed
    1. Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48:1000–1007. - PubMed
    1. Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Makuch R, Rendon G Portal Hypertension Collaborative Group. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol . 2009;7:689–695. - PMC - PubMed
    1. Kaneko J, Sugawara Y, Matsui Y, Ohkubo T, Makuuchi M. Normal splenic volume in adults by computed tomography. Hepatogastroenterology . 2002;49:1726–1727. - PubMed